Professor of Medicine, Johns Hopkins University School of Medicine; Director, Hopkins Lupus Center
Rheumatology
Dr. Michelle A. Petri, MD
|
|
Give Review
Michelle Petri works in the field of Rheumatology. She graduated from Harvard Medical School. Harvard Medical School is a one of the best medicals schools. Harvard Medical School is ranked 1/12 in Research/PrimaryCare. She received awards:"America's Top Doctors", "CMS Meaningful Use Stage 1 Certification", "Top Doctors:Baltimore Area", "Top Doctors:Washington-Baltimore", "Fellow (FACR)", "Super Doctor" and "Fellow". Michelle Petri has written publications. She has 88 publications published with PubMed. The lastest paper is: 'Cumulative corticosteroids over 52 weeks in patients with systemic lupus erythematosus: Pooled analyses from the phase III belimumab trials.' Dr. Michelle A. Petri accepts Medicare payments and is registered with Medicare.gov.
Publications
- Association of Antibodies to Interferon-Inducible Protein-16 With Markers of More Severe Disease in Primary Sjögren's Syndrome.
- Efficacy and safety of subcutaneous tabalumab in patients with systemic Lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, ...
- Self-reactive IgE exacerbates interferon responses associated with autoimmunity.
- Longitudinal Evaluation of Lipoprotein Variables in Systemic Lupus Erythematosus Reveals Adverse Changes with Disease Activity and Prednisone and More Favorable Profil...
- Healthcare costs of pregnancy in systemic Lupus erythematosus: retrospective observational analysis from a US health claims database.
- Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence.
- Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices.
- The relevance of "non-criteria" clinical manifestations of Antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force R...
- Interferon regulatory factor 1 marks activated genes and can induce target gene expression in systemic Lupus erythematosus.
- Genetic association of CD247 (CD3ζ) with SLE in a large-scale multiethnic study.
- Interferon regulatory factor 1 and histone H4 acetylation in systemic Lupus erythematosus.
- Anti-C1q antibodies in systemic Lupus erythematosus.
- Risk factors for cataracts in systemic Lupus erythematosus (SLE).
- Predictors of incident depression in systemic Lupus erythematosus.
- Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA.
- The IRF5-TNPO3 association with systemic Lupus erythematosus (SLE) has two components that other autoimmune disorders variably share.
- An integrated extrapolation of long-term outcomes in systemic Lupus erythematosus: analysis and simulation of the Hopkins Lupus Cohort.
- Brief Report: A Polymorphism in TLR2 Is Associated With Arterial Thrombosis in a Multiethnic Population of Patients With Systemic Lupus Erythematosus.
- Prevention and management of co-morbidities in SLE.
- Lupus Nephritis Susceptibility Loci in Women with Systemic Lupus Erythematosus.
- Fcγ Receptor IIIa Single-Nucleotide Polymorphisms and Haplotypes Affect Human IgG Binding and Are Associated With Lupus Nephritis in African Americans.
- 14th International Congress on Antiphospholipid Antibodies Task Force. Report on Antiphospholipid syndrome laboratory diagnostics and trends.
- Factors associated with damage accrual in patients with systemic Lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Incep...
- Burden of corticosteroid use in patients with systemic Lupus erythematosus: results from a Delphi panel.
- American College of Rheumatology Criteria at Inception, and Accrual over 5 Years in the SLICC Inception Cohort.
- Two Functional Lupus-Associated BLK Promoter Variants Control Cell-Type- and Developmental-Stage-Specific Transcription.
- A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic Lupus er...
- Incidence of lymphoma associated with underlying Lupus: lessons learned from observational studies.
- End-Stage Renal Disease in African Americans With Lupus Nephritis Is Associated With APOL1.
- Allelic-dependent expression of an activating fc receptor on B cells enhances humoral immune responses.
- FcγRIIIa SNPs and haplotypes affect human IgG binding and association with Lupus nephritis in African Americans.
- Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus.
- Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE tri...
- Transient ischemic attack and stroke in systemic Lupus erythematosus.
- Preferential binding to Elk-1 by SLE-associated IL10 risk allele upregulates IL10 expression.
- End-stage kidney Disease in African Americans with lupus nephritis associates with APOL1.
- Impaired Health Status and the Effect of Pain and Fatigue on Functioning in Clinical Trial Patients with Systemic Lupus Erythematosus.
- 2013 update: hopkins Lupus cohort.
- Value of isolated IgA anti-β2 GPI positivity in the diagnosis of the Antiphospholipid syndrome.
- Baseline Predictors of Systemic Lupus Erythematosus Flares: Data From the Combined Placebo Groups in the Phase III Belimumab Trials.
- Vitamin D deficiency does not predict progression of coronary artery Calcium, carotid intima-media thickness or high-sensitivity C-reactive protein in systemic lupus e...
- Vitamin D in Systemic Lupus Erythematosus: Modest Association With Disease Activity and the Urine Protein-to-Creatinine Ratio.
- Omega-3 in SLE: a double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and Disease activity in systemic lupus erythematosus.
- Variable Association of Reactive Intermediate Genes with Systemic Lupus Erythematosus in Populations with Different African Ancestry.
- Predictors of self-reported health-related quality of life in systemic Lupus erythematosus.
- Predictors of corticosteroid tapering in SLE patients: the Hopkins Lupus Cohort.
- Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic Lupus erythematosus: results from two randomized, double-blind, placebo-controlled...
- Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic Lupus eryt...
- Fine mapping of Xq28: both MECP2 and IRAK1 contribute to risk for systemic Lupus erythematosus in multiple ancestral groups.
- MicroRNA-3148 Modulates Allelic Expression of Toll-Like Receptor 7 Variant Associated with Systemic Lupus Erythematosus.
- Admixture Mapping in Lupus Identifies Multiple Functional Variants within IFIH1 Associated with Apoptosis, Inflammation, and Autoantibody Production.
- Sifalimumab, a human anti-interferon-a monoclonal antibody, in systemic Lupus erythematosus: A phase 1 randomized controlled, dose-escalation study.
- Utility of Antiphosphatidylserine/Prothrombin and IgA Antiphospholipid Assays in Systemic Lupus Erythematosus.
- Efficacy and safety of epratuzumab in patients with moderate/severe active systemic Lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, pl...
- Brief Report: Single-nucleotide polymorphisms in VKORC1 are risk factors for systemic Lupus erythematosus in Asians.
- Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on Disease activity across multiple organ domains in patients with systemic lupus erythematosus: co...
- Impact of genetic ancestry and socio-demographic status on the clinical expression of systemic Lupus erythematosus in Amerindian-European populations.
- Two independent functional risk haplotypes in TNIP1 are associated with systemic Lupus erythematosus.
- Semiquantified Noncalcified Coronary Plaque in Systemic Lupus Erythematosus.
- Predictors of organ damage in systemic Lupus erythematosus: The hopkins' Lupus cohort.
- Seasonal Variation in the Activity of Systemic Lupus Erythematosus.
- Urinary Vascular Cell Adhesion Molecule, But Not Neutrophil Gelatinase-associated Lipocalin, Is Associated with Lupus Nephritis.
- Differences between Male and Female Systemic Lupus Erythematosus in a Multiethnic Population.
- Low socioeconomic status is associated with cardiovascular risk factors and outcomes in systemic Lupus erythematosus.
- Evidence for gene-gene epistatic interactions among susceptibility loci for systemic Lupus erythematosus.
- IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with sys...
- Identification of novel genetic susceptibility loci in African American Lupus patients in a candidate gene association study.
- Genetic analyses of interferon pathway-related genes reveals multiple new loci associated with systemic Lupus erythematosus (SLE).
- The role of genetic variation near interferon-kappa in systemic Lupus erythematosus.
- A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic Lupus erythematosus.
- A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic Lupus erythematosus.
- Novel evidence-based systemic Lupus erythematosus responder index.
- High-density genotyping of STAT4 reveals multiple haplotypic associations with systemic Lupus erythematosus in different racial groups.
- Variants within MECP2, a key transcription regulator, are associated with increased susceptibility to Lupus and differential gene expression in patients with systemic ...
- Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic Lupus erythematosus.
- The TNFalpha locus is altered in monocytes from patients with systemic Lupus erythematosus.
- The effect of combined estrogen and progesterone hormone replacement therapy on Disease activity in systemic lupus erythematosus: a randomized trial.
- Effects of prasterone on Disease activity and symptoms in women with active systemic lupus erythematosus.
- Neuropsychiatric systemic Lupus erythematosus: miles to go before we sleep.
- Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results.
- H3K4 tri-methylation breadth at transcription start sites impacts the transcriptome of systemic Lupus erythematosus.
- Lupus risk variants in the PXK locus alter B-cell receptor internalization.
- Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimum...
- The SLE Transcriptome Exhibits Evidence of Chronic Endotoxin Exposure and Has Widespread Dysregulation of Non-Coding and Coding RNAs.
- PTPN22 Association in Systemic Lupus Erythematosus (SLE) with Respect to Individual Ancestry and Clinical Sub-Phenotypes.
- Cumulative corticosteroids over 52 weeks in patients with systemic Lupus erythematosus: Pooled analyses from the phase III belimumab trials.
- Changes in Antiphospholipid Antibody Titers during Pregnancy: Data from the PROMISSE Study.
Schools
HARVARD MED SCH
Mass Gen Hospital
Procedures Preformed
- Steroid Injection
Conditions Treated
- Acute Sinusitis
- Antiphospholipid Syndrome (APS)
- Arthritis
- Asthma
- View All
Doctors Specialties
- Rheumatology
Accepted Insurances
Awards
- America's Top Doctors
- CMS Meaningful Use Stage 1 Certification
- Top Doctors:Baltimore Area
- Top Doctors:Washington-Baltimore
- Fellow (FACR)
- Super Doctor
- Fellow
Education
-
UCSF -
Massachusetts General Hospital -
Harvard Medical School
Hospital
-
Johns Hopkins Hospital -
Johns Hopkins Bayview Medical Center
Drug Facts
| NPI NUMBER | 1548206683 | |
| NPPES Provider LastName | PETRI | |
| NPPES Provider FirstName | MICHELLE | |
| NPPES Provider ZIPCode | 212870005 | |
| NPPES Provider State | MD | |
| Specialty Description | Rheumatology | |
| Total Claim Count | 1833.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 22.0 | |
| Percent Opioid Claims | 1.2 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1548206683 |
| Last Name Of The Provider | PETRI |
| First Name Of The Provider | MICHELLE |
| View All |
Similar Doctors
|
|
Dr. Shikha M. Nanda, MD |
|
|
Dr. Julius Birnbaum, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nazi Farsi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rebecca L. Manno, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lawrence D. Weber, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carol M. Ziminski, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Zaki Abou Zahr, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Uzma J. Haque, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Inder P. Singh, MD
This Doctor is OpenDoctor Recommended.
|